REGN Stock Summary and Trading Ideas (Regeneron Pharmaceuticals | NASDAQ:REGN)

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Regeneron Pharmaceuticals trades on the NASDAQ stock market under the symbol REGN.

As of April 16, 2026, REGN stock price declined to $746.00 with 455,325 million shares trading.

REGN has a beta of 0.51, meaning it tends to be less sensitive to market movements. REGN has a correlation of 0.03 to the broad based SPY ETF.

REGN has a market cap of $78.40 billion. This is considered a Large Cap stock.

Last quarter Regeneron Pharmaceuticals reported $4 billion in Revenue and $11.44 earnings per share. This beat revenue expectation by $86 million and exceeded earnings estimates by $1.75.

In the last 3 years, REGN traded as high as $1,211.20 and as low as $476.49.

The top ETF exchange traded funds that REGN belongs to (by Net Assets): VTI, VOO, QQQ, IVV, SPY.

REGN has outperformed the market in the last year with a return of +34.4%, while the SPY ETF gained +31.9%. However, in the most recent history, REGN shares have underperformed the stock market with its stock returning +0.7% in the last 3 month period and -4.0% for the last 2 week period, while SPY has returned +1.6% and +7.1%, respectively.

REGN support price is $741.23 and resistance is $766.63 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that REGN shares will trade within this expected range on the day.